Table 2:

Primary and secondary efficacy outcomes

	FGFR2 fusions or rearrangements (n=107)	Other FGF/FGFR alterations (n=20)	No FGF/FGFR alterations (n=18)
Proportion of patients with an objective response	35·5% (26·5 to 45·4)	0	0
Best overall response*
Complete response	3 (2·8%)	0	0
Partial response	35 (32·7%)	0	0
Stable disease	50 (46·7%)	8 (40·0%)	4 (22·2%)
Progressive disease	16 (14·9%)	7 (35·0%)	11 (61·1%)
Not evaluable	3 (2·8%)	5 (25·0%)	3 (16·7%)
Duration of response
Patients with events	21/38 (55%)	0	0
Patients censored	17/38 (45%)	0	0
Median duration of response, months	7·5 (5·7 to 14·5)	..	..
Kaplan-Meier estimated probability of retaining a response
At 6 months	68% (49 to 82)	..	..
At 12 months	37% (19 to 56)	..	..
Proportion of patients with disease control	82% (74 to 89)	40% (19 to 64)	22% (6 to 48)
Progression-free survival
Patients with events	71 (66%)	17 (85%)	16 (89%)
Patients censored	36 (34%)	3 (15%)	2 (11%)
Median, months	6·9 (6·2 to 9·6)	2·1 (1·2 to 4·9)	1·7 (1·3 to 1·8)
Kaplan-Meier estimates of progression-free survival
At 6 months	62% (52 to 70)	25% (8 to 47)	6% (<1 to 25)
At 12 months	29% (19 to 40)	0	0
Overall survival†
Patients with events	40 (37%)	16 (80%)	14 (78%)
Patients censored	67 (63%)	4 (20%)	4 (22%)
Median overall survival, months	21·1 (14·8 to not estimable)	6·7 (2·1 to 10·6)	4·0 (2·3 to 6·5)
Kaplan-Meier estimates of overall survival
At 6 months	89% (81 to 93)	51% (26 to 71)	31% (11 to 54)
At 12 months	68% (56 to 76)	23% (7 to 43)	13% (2 to 33)

Data are % (95% CI), n (%), or months (95% CI). FGFR=fibroblast growth factor receptor.

^*Assessed and response confirmed by independent reviewer (95% CIs not available for individual response values).

^†Overall survival data were not mature at data cutoff.